Peripheral vascular disease risk in diabetic individuals without coronary heart disease.

[1]  J. Bosch,et al.  Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. , 2018, Lancet.

[2]  Khalid Yusoff,et al.  Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. , 2017, Lancet.

[3]  F. Kronenberg,et al.  Measures of chronic kidney disease and risk of incident peripheral artery disease: a collaborative meta-analysis of individual participant data. , 2017, The lancet. Diabetes & endocrinology.

[4]  J. Berger,et al.  Underuse of Prevention and Lifestyle Counseling in Patients With Peripheral Artery Disease. , 2017, Journal of the American College of Cardiology.

[5]  L. Fleisher,et al.  2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2017, Journal of the American College of Cardiology.

[6]  J. Berger,et al.  Diabetes mellitus is a coronary heart disease risk equivalent for peripheral vascular disease , 2017, American heart journal.

[7]  R. Stein,et al.  Association Between Physical Activity and Peripheral Artery Disease and Carotid Artery Stenosis in a Self-Referred Population of 3 Million Adults , 2015, Arteriosclerosis, thrombosis, and vascular biology.

[8]  Binita Shah,et al.  Diabetes and Vascular Disease in Different Arterial Territories , 2014, Diabetes Care.

[9]  Igor Rudan,et al.  Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis , 2013, The Lancet.

[10]  J. Cooke,et al.  Alternative ankle-brachial index method identifies additional at-risk individuals. , 2013, Journal of the American College of Cardiology.

[11]  J. Saaddine,et al.  Achievement of goals in U.S. diabetes care, 1999-2010. , 2013, The New England journal of medicine.

[12]  Yu Guo,et al.  Association between advanced age and vascular disease in different arterial territories: a population database of over 3.6 million subjects. , 2013, Journal of the American College of Cardiology.

[13]  M. M. Joosten,et al.  Associations between conventional cardiovascular risk factors and risk of peripheral artery disease in men. , 2012, JAMA.

[14]  G. Tomaselli,et al.  Letter by Tomaselli and Holmes regarding article, "2011 ASA/ACCF/AHA/AANN/AANS/ACR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease". , 2012, Circulation.

[15]  J. Shaw,et al.  IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. , 2011, Diabetes research and clinical practice.

[16]  Gary Friday,et al.  2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease. , 2011, Stroke.

[17]  Deepak L. Bhatt,et al.  Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. , 2010, JAMA.

[18]  M. Criqui,et al.  Atherosclerotic Peripheral Vascular Disease Symposium II: screening for atherosclerotic vascular diseases: should nationwide programs be instituted? , 2008, Circulation.

[19]  W. Katon,et al.  Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization. , 2008, The American journal of managed care.

[20]  T. Manolio,et al.  Intrinsic contribution of gender and ethnicity to normal ankle-brachial index values: the Multi-Ethnic Study of Atherosclerosis (MESA). , 2007, Journal of vascular surgery.

[21]  Rodney A. White,et al.  ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography , 2006, Circulation.

[22]  B. Howard,et al.  Coronary heart disease risk equivalence in diabetes depends on concomitant risk factors. , 2006, Diabetes care.

[23]  Seppo Lehto,et al.  Type 2 diabetes as a "coronary heart disease equivalent": an 18-year prospective population-based study in Finnish subjects. , 2005, Diabetes care.

[24]  H. Resnick,et al.  Prevalence of elevated ankle-brachial index in the United States 1999 to 2002. , 2005, The American journal of medicine.

[25]  Elizabeth Selvin,et al.  Prevalence of and Risk Factors for Peripheral Arterial Disease in the United States: Results From the National Health and Nutrition Examination Survey, 1999–2000 , 2004, Circulation.

[26]  P. Sorlie,et al.  Prevalence of lower-extremity disease in the US adult population >=40 years of age with and without diabetes: 1999-2000 national health and nutrition examination survey. , 2004, Diabetes care.

[27]  J. Mckenney,et al.  National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) , 2002 .

[28]  K. Johansen,et al.  Lower-extremity peripheral arterial disease among patients with end-stage renal disease. , 2001, Journal of the American Society of Nephrology : JASN.

[29]  S. Yusuf,et al.  Impact of Diabetes on Long-Term Prognosis in Patients With Unstable Angina and Non–Q-Wave Myocardial Infarction: Results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry , 2000, Circulation.

[30]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[31]  R. Holman,et al.  Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. , 1999, JAMA.

[32]  Philip D. Harvey,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 , 1998, BMJ.

[33]  R. Holman,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. , 1998 .

[34]  R. Holman,et al.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.

[35]  J. Shaw,et al.  IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. , 2011, Diabetes research and clinical practice.

[36]  S. Grundy,et al.  National Cholesterol Education Program Third Report of the National Cholesterol Education Program ( NCEP ) Expert Panel on Detection , Evaluation , and Treatment of High Blood Cholesterol in Adults ( Adult Treatment Panel III ) Final Report , 2022 .